Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
UroGen PharmaFRA:UR8 +7.58%63 PS Ratio is 15.00 as of Jul. 22, 2026, which is 42% above its 10-year median of 10.58. GuruFocus rates FRA:UR8 with a GF Score™ of 63/100 and a GF Value™ of €18.14 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 930 Biotechnology companies, UroGen Pharma ranks worse than 61.08% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, UroGen Pharma's share price is €36.91.
UroGen Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €2.46. Hence, UroGen Pharma's PS Ratio for today is 15.00.
Warning Sign:
UroGen Pharma Ltd stock PS Ratio (=15.31) is close to 5-year high of 15.31.
The historical rank and industry rank for UroGen Pharma's PS Ratio or its related term are showing as below:
FRA:UR8'
s PS Ratio Range Over the Past 10 Years
Min: 2.07 Med: 10.58 Max: 34620
Current: 15.31
During the past 11 years, UroGen Pharma's highest PS Ratio was 34620.00. The lowest was 2.07. And the median was 10.58.
FRA:UR8's PS Ratio is ranked worse than 61.08% of 930
companies
in the Biotechnology industry
Industry Median: 9.205
vs FRA:UR8: 15.31
UroGen Pharma Ltd revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of UroGen Pharma was 41.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -6.80% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 22.70% per year.
During the past 11 years, UroGen Pharma's highest 3-Year average Revenue per Share Growth Rate was 1313.10% per year. The lowest was -91.20% per year. And the median was -0.70% per year.
Back to Basics: PS Ratio
UroGen Pharma (FRA:UR8) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
UroGen Pharma PS Ratio Related Terms
UroGen Pharma PS Ratio Historical Data
* Premium members only.
The historical data trend for UroGen Pharma's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, UroGen Pharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UroGen Pharma PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UroGen Pharma's PS Ratio distribution charts can be found below:
* The bar in red indicates where UroGen Pharma's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
UroGen Pharma's Share Price of today is €36.91. UroGen Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.46.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
UroGen Pharma (FRA:UR8) has a PS Ratio of 15.00 as of Jul. 22, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on UroGen Pharma and its competitors. This is 42% above median its historical median of 10.58. Over the past decade, UroGen Pharma's PS Ratio has ranged from 2.07 to 34,620.00. According to the industry distribution chart, UroGen Pharma ranks #568 out of 930 companies in the Biotechnology industry, placing it in the top 61.1%.
Is UroGen Pharma's PS Ratio too high?
UroGen Pharma's current PS Ratio of 15.00 is 42% above median its 10-year median of 10.58. Over the past 10 years, this metric has ranged from a low of 2.07 to a high of 34,620.00. The Biotechnology industry median PS Ratio is 9.21. UroGen Pharma's value of 15.00 is 63% above this industry median. Based on the distribution chart, UroGen Pharma ranks #568 out of 930 companies in the Biotechnology industry, which is below the industry midpoint. Overall, UroGen Pharma has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UroGen Pharma's PS Ratio compare to SEPN and FTRE?
According to the Biotechnology industry distribution chart, UroGen Pharma ranks #568 out of 930 companies for PS Ratio. This places UroGen Pharma in the lower half of its industry. The industry median PS Ratio is 9.21. UroGen Pharma's value of 15.00 is 63% above this benchmark. Historically, UroGen Pharma's own PS Ratio has ranged from 2.07 to 34,620.00 over the past decade. While the company's 10-year median is 10.58 vs. the industry median of 9.21, UroGen Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.21, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. UroGen Pharma's current PS Ratio of 15.00 is 63% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on UroGen Pharma and its competitors. For the Biotechnology industry, the median PS Ratio is 9.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. UroGen Pharma's current PS Ratio is 15.00, which is 42% above median its own 10-year median of 10.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UroGen Pharma stock overvalued right now?
Based on GuruFocus' analysis, UroGen Pharma (FRA:UR8) is currently considered Significantly Overvalued. The stock's GF Value™ is €18.14, compared to a current price of €36.91 — trading 103.5% above its estimated fair value. The current PS Ratio is 15.00, which is 42% above median its 10-year median of 10.58 and 63% above the Biotechnology industry median of 9.21. UroGen Pharma's overall GF Score™ is 63/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For UroGen Pharma (FRA:UR8), the current PS Ratio is 15.00 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UroGen Pharma (FRA:UR8) Overvalued in 2026?
Based on GuruFocus' analysis, UroGen Pharma stock appears to be overvalued.
The current stock price of €36.91 is trading 103.5% above its estimated GF Value™ of €18.14.
GuruFocus considers UroGen Pharma to be Significantly Overvalued.
Key valuation signals for FRA:UR8:
PS Ratio: 15.00 (42% above median its 10-year median of 10.58)
GF Value™: €18.14 vs. price of €36.91 (103.5% above fair value)
Industry Position: 63% above the Biotechnology median (#568 of 930)
No single metric tells the full story. See the FRA:UR8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
63GF Score
Get the complete analysis for FRA:UR8
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:UR8 has been successfully added to your 
